Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 20.4% in January

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 69,500 shares, a decline of 20.4% from the December 31st total of 87,300 shares. Approximately 10.1% of the shares of the company are sold short. Based on an average trading volume of 99,900 shares, the days-to-cover ratio is currently 0.7 days.

Qualigen Therapeutics Trading Up 7.0 %

Qualigen Therapeutics stock traded up $0.23 during midday trading on Monday, hitting $3.50. The stock had a trading volume of 56,798 shares, compared to its average volume of 103,590. Qualigen Therapeutics has a 52-week low of $2.96 and a 52-week high of $29.43. The firm’s fifty day moving average is $4.18 and its two-hundred day moving average is $6.90.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.